LAWRENCE, Mass., May 19, 2014 /PRNewswire/ -- NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, is proud to share a current NxStage® System One™ user's story of courage, persistence and determination. Despite losing both of his kidneys to cancer, Greg, a 65-year-old avid runner, was able to accomplish his goal of running a half marathon this past February in Sacramento. For Greg, more frequent home hemodialysis (HHD) with the NxStage System One helped give him the freedom to stay active, and the opportunity to continue running and training on his own schedule.
"I've been a runner all my life and that helps me deal with outside stress," said Greg. "It's important for everyone to have a sense of independence and control, and NxStage has given that to me. NxStage has changed my life by helping me live my life the way I want."
For Greg, his success in completing a half marathon is an opportunity to inspire more than one million people worldwide who suffer from End Stage Renal Disease and other types of kidney failure. Through the years, Greg has logged 32 ultra-marathons and served as the Western States 100 Mile Endurance Run Race Director for over 10 years. After surviving cancer, the removal of his kidneys could have been devastating to Greg's active lifestyle; however, Greg found home hemodialysis. Weeks following the surgery, he began treatment with the NxStage System One. With help from his wife and care partner Mary, Greg dialyzes five to six days a week at his Sacramento home on his own time and in his own space, providing him the freedom to maintain a consistent training schedule.
"We work hard to create treatment solutions to benefit the lives of our patients, particularly by giving them additional freedom to pursue their individual lifestyles," said NxStage President, Joe Turk. "We congratulate Greg and are delighted that he credits home hemodialysis with helping him pursue his passion."
Hear Greg share his journey with kidney disease in his video, Life is a Marathon. To learn more about NxStage and the System One, visit www.nxstage.com or join the conversation on Facebook at facebook.com/NxStage, Twitter at @NxStage and YouTube at youtube.com/user/NxStage.
Despite the health benefits that more frequent home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
About the NxStage System One The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact: Meredith D'Agostino 451 Marketing, on behalf of NxStage Medical, Inc. email@example.com (516) 884-7162
SOURCE NxStage Medical, Inc.